Black Diamond Therapeutics Inc (BDTX) Stock Analysis
Verdict: HOLD
BDTX is a high-beta oncology play transitioning from cash-burn to revenue-generation, backed by a massive $8.00 analyst price target.
Investment score: 62/100
Analysis as of
Is Black Diamond Therapeutics Inc stock worth reviewing? The TradeMates thesis
BDTX offers a rare combination of clinical-stage upside and a fortress balance sheet (8.4 current ratio) at a deep discount to peers.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 80/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Black Diamond Therapeutics Inc opportunities and risks
What speaks for BDTX
- Clinical Pivot to Commercialization
What speaks against BDTX
- Clinical Trial Binary Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BDTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -22.2% |
| HURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -16.4% |
| IMUX | n/a | 0.0x | 0.7x | 0.0% | 0.0% | -71.1% |
| PLX | 10.3x | 2.1x | 5.9x | 70.0% | 20.1% | 9.2% |
| ABOS | n/a | 0.0x | n/a | 0.0% | 0.0% | -79.9% |
| SPRO | 9.8x | 2.8x | 6.9x | 99.5% | 27.8% | 4.8% |
| Peer median | n/a | 0.0x | 0.7x | 0.0% | 0.0% | -16.4% |
Frequently asked questions about Black Diamond Therapeutics Inc (BDTX)
Is BDTX stock a good investment?
The TradeMates model rates Black Diamond Therapeutics Inc as HOLD with an investment score of 62/100. BDTX offers a rare combination of clinical-stage upside and a fortress balance sheet (8.4 current ratio) at a deep discount to peers. This is algorithmic model output, not personal investment advice.
Is BDTX stock a buy?
The TradeMates model verdict for BDTX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.